Prospects for a dengue virus vaccine.
The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.
Whitehead
Stephen S
SS
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. swhitehead@niaid.nih.gov
Blaney
Joseph E
JE
Durbin
Anna P
AP
Murphy
Brian R
BR
D000818:Animals; D019067:Antibody-Dependent Enhancement; D001210:Asia, Southeastern / Q000453:epidemiology; D002489:Central America / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D003715:Dengue / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control* / Q000821:virology; D053059:Dengue Vaccines / Q000276:immunology*; D003716:Dengue Virus / Q000145:classification / Q000235:genetics / Q000276:immunology*; D006801:Humans; D013020:South America / Q000453:epidemiology; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D053059:Dengue Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic